De-Risk & Accelerate Your Journey To The Clinic With Your Cell Therapy CDMO Partner

manufactured in our GMP facility

T cells, NK cells, T regs, MSCs, iPS, immortalized cell lines…

Process Development, Optimization, Scale up, Analytical & Potency test development

From Bench to GMP_Cell-Easy
Four technicians working in a GMP manufacturing environment. One is performing manipulations inside a biosafety cabinet performing manipulations, while the other three stand in the background.- Cell-Easy

Cell therapy programs fail more often from execution gaps than from bad science. Processes that aren’t robust, documentation that doesn’t hold up to scrutiny, timelines that slip when complexity hits. We work with our partners to close those gaps, bringing the technical depth and manufacturing expertise to keep your program on track from development through to clinical success.

  • ScaleReady Awards G-Rex® Grant to Support Cell-Easy as a European Hub for G-Rex®-Based Manufacturing

    ScaleReady Awards G-Rex® Grant to Support Cell-Easy as a European Hub for G-Rex®-Based Manufacturing

    Toulouse, 2026 June 11th ScaleReady, a joint venture between Wilson Wolf and Bio-Techne and provider of scalable cell culture technologies, has awarded a G-Rex® Grant to Cell-Easy to support the development of a European hub for G-Rex®-based cell therapy manufacturing within the French CDMO. G-Rex® is widely recognized as a leading platform for scalable cell…

    Learn more: ScaleReady Awards G-Rex® Grant to Support Cell-Easy as a European Hub for G-Rex®-Based Manufacturing
  • betacure_Cell-Easy

    Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges

    Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies directly applicable to biotech and pharma iPSC programs. Toulouse, 2026 April 14th Tackling one of the main bottlenecks in iPSC-derived therapies Scale-up remains one of the most…

    Learn more: Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges
  • CHU Toulouse Cell Easy

    CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis

    CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis Toulouse, January 22, 2026 — Cell-Easy, a CDMO specialized in the development and GMP manufacturing of Advanced Therapy Medicinal Products (ATMPs), announces a new clinical milestone achieved in close collaboration with Toulouse University Hospital (CHU Toulouse).…

    Learn more: CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis